Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Isomorphic Labs, an AI drug-discovery spin-off from Google's DeepMind, has raised $5 billion in a Series C funding round. The company plans to use the capital to advance its AI-driven drug candidates into clinical trials for oncology and immunology.
Why it matters
This massive investment underscores the growing intersection of AI and biotechnology, potentially accelerating the development of new life-saving medicines.
Isomorphic Labs , the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.
The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model , said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.
Also covering this story
2 other newsrooms covered this event. We read each version separately.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in